American Century Companies
EDIT icon

American Century Companies’s Editas Medicine EDIT Stock Holding History

American Century Companies’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$300K Buy
+92,596
New +$271K ﹤0.01% 2701
2024
Q4 		– Sell
-147,971
Closed -$505K – 2905
2024
Q3 		$505K Buy
147,971
+21,731
+17% +$94.6K ﹤0.01% 2471
2024
Q2 		$590K Buy
126,240
+15,088
+14% +$85.1K ﹤0.01% 2380
2024
Q1 		$825K Buy
111,152
+29,094
+35% +$242K ﹤0.01% 2230
2023
Q4 		$831K Buy
82,058
+28,250
+53% +$248K ﹤0.01% 2150
2023
Q3 		$420K Buy
53,808
+19,451
+57% +$167K ﹤0.01% 2336
2023
Q2 		$283K Buy
34,357
+16,827
+96% +$147K ﹤0.01% 2411
2023
Q1 		$123K Buy
17,530
+3,507
+25% +$31.2K ﹤0.01% 2515
2022
Q4 		$124K Buy
+14,023
New +$154K ﹤0.01% 2425
2022
Q2 		– Sell
-198,110
Closed -$3.77M – 2325
2022
Q1 		$3.77M Hold
198,110
– – ﹤0.01% 1200
2021
Q4 		$5.26M Hold
198,110
– – ﹤0.01% 1043
2021
Q3 		$8.14M Buy
198,110
+343
+0.2% +$18.8K 0.01% 903
2021
Q2 		$11.2M Hold
197,767
– – 0.01% 788
2021
Q1 		$8.31M Sell
197,767
-24,243
-11% -$1.38M 0.01% 817
2020
Q4 		$15.6M Sell
222,010
-68,547
-24% -$2.82M 0.01% 675
2020
Q3 		$8.15M Hold
290,557
– – 0.01% 747
2020
Q2 		$8.6M Sell
290,557
-51,332
-15% -$1.34M 0.01% 711
2020
Q1 		$6.78M Sell
341,889
-33,994
-9% -$857K 0.01% 676
2019
Q4 		$11.1M Buy
375,883
+488
+0.1% +$12.2K 0.01% 654
2019
Q3 		$8.54M Sell
375,395
-60,438
-14% -$1.5M 0.01% 645
2019
Q2 		$10.8M Buy
435,833
+49,567
+13% +$1.18M 0.01% 617
2019
Q1 		$9.44M Buy
386,266
+39,592
+11% +$896K 0.01% 631
2018
Q4 		$7.89M Buy
+346,674
New +$9.43M 0.01% 662
2018
Q2 		– Sell
-192,873
Closed -$6.39M – 1302
2018
Q1 		$6.39M Sell
192,873
-110,087
-36% -$3.92M 0.01% 771
2017
Q4 		$9.31M Sell
302,960
-9,269
-3% -$233K 0.01% 658
2017
Q3 		$7.5M Buy
+312,229
New +$5.94M 0.01% 735

Other funds holding EDIT

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

American Century Companies's EDIT Position: Q2 2026 in Review

American Century Companies opened a new position in Editas Medicine (EDIT) in Q2 2026: 92,596 shares worth $300K. The stake represents ﹤0.01% of the portfolio and ranks #2701 among its holdings. This is a return to the name: American Century Companies previously reported a position in EDIT as recently as Q3 2024.

American Century Companies first reported a position in EDIT in Q3 2017 and has held it in 26 quarters since. The position peaked at $15.6M in Q4 2020. 216 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.

  • American Century Companies held 92,596 shares of Editas Medicine worth $300K as of Q2 2026.
  • Editas Medicine was a new American Century Companies position in Q2 2026.
  • Editas Medicine made up ﹤0.01% of American Century Companies's portfolio in Q2 2026, its #2701 holding.
  • American Century Companies first reported a position in Editas Medicine in Q3 2017 and has held it in 26 quarters since.
  • American Century Companies's Editas Medicine position peaked at $15.6M in Q4 2020.
  • 216 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.

Based on American Century Companies's 13F filing for Q2 2026, filed 12 Aug 2026.